Picture loading failed.

Pre-Made Tregalizumab biosimilar, Whole mAb, Anti-CD4 Antibody: Anti-IMD79/OKT4D therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Tregalizumab is an immunomodulator. It is also known as BT-061. Tregalizumab binds to domain 2 of CD4, and activates Regulatory T cells (Tregs).

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-594-1mg 1mg 3090
GMP-Bios-ab-594-10mg 10mg Inquiry
GMP-Bios-ab-594-100mg 100mg Inquiry
GMP-Bios-ab-594-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Tregalizumab biosimilar, Whole mAb, Anti-CD4 Antibody: Anti-IMD79/OKT4D therapeutic antibody
INN Name Tregalizumab
TargetCD4
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2010
Year Recommended2011
CompaniesBiotest AG
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedMultiple sclerosis;Plaque psoriasis;Rheumatoid arthritis
Development Techna